TY - JOUR
T1 - Positron emission tomography-based response to target and immunotherapies in oncology
AU - Donegani, Maria Isabella
AU - Ferrarazzo, Giulia
AU - Marra, Stefano
AU - Miceli, Alberto
AU - Raffa, Stefano
AU - Bauckneht, Matteo
AU - Morbelli, Silvia
PY - 2020/8
Y1 - 2020/8
N2 - 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patient’s level. The present review aims to discuss available evidence related to the use of [18F]FDG PET (Positron Emission Tomography) to evaluate the response to target therapies and immune checkpoint inhibitors. Criteria proposed for the standardization of the definition of the PET-based response and complementary value with respect to morphological imaging are commented on. The use of PET-based assessment of the response through metabolic pathways other than glucose metabolism is also relevant in the framework of personalized cancer treatment. A brief discussion of the preliminary evidence for the use of non-FDG PET tracers in the evaluation of the response to new therapies is also provided.
AB - 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patient’s level. The present review aims to discuss available evidence related to the use of [18F]FDG PET (Positron Emission Tomography) to evaluate the response to target therapies and immune checkpoint inhibitors. Criteria proposed for the standardization of the definition of the PET-based response and complementary value with respect to morphological imaging are commented on. The use of PET-based assessment of the response through metabolic pathways other than glucose metabolism is also relevant in the framework of personalized cancer treatment. A brief discussion of the preliminary evidence for the use of non-FDG PET tracers in the evaluation of the response to new therapies is also provided.
KW - Immunotherapy
KW - Positron emission tomography
KW - Response assessment, PERCIST criteria
KW - Target therapy
UR - http://www.scopus.com/inward/record.url?scp=85088810979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088810979&partnerID=8YFLogxK
U2 - 10.3390/medicina56080373
DO - 10.3390/medicina56080373
M3 - Review article
C2 - 32722205
AN - SCOPUS:85088810979
VL - 56
SP - 1
EP - 22
JO - Medicina
JF - Medicina
SN - 1010-660X
IS - 8
M1 - 373
ER -